145 related articles for article (PubMed ID: 20167205)
1. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
[TBL] [Abstract][Full Text] [Related]
2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
6. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
[TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
8. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
9. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
10. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
Becker RV; Dembek C
J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
[TBL] [Abstract][Full Text] [Related]
11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
12. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
[TBL] [Abstract][Full Text] [Related]
13. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
[TBL] [Abstract][Full Text] [Related]
14. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
15. State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment.
Shipova EG; Spirin NN; Kasatkin DS; Shumakov EI; Stepanov IO
Neurosci Behav Physiol; 2009 Jan; 39(1):47-51. PubMed ID: 19089623
[TBL] [Abstract][Full Text] [Related]
16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
17. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
18. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
[TBL] [Abstract][Full Text] [Related]
19. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
